CD27 and neoplasm: Given the reported conflicting roles of CD27 in both promoting and/or hindering anti-tumour immunity in the literature, the downregulation of CD27 on T cells following neoadjuvant treatment in OGJ patients in this study may be detrimental or beneficial in promoting anti-tumour immunity and may likely be dependent on the tumour immune contexture within patients.